loading
Schlusskurs vom Vortag:
$9.29
Offen:
$9.27
24-Stunden-Volumen:
614.33K
Relative Volume:
0.55
Marktkapitalisierung:
$780.89M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-209.96M
KGV:
-3.0633
EPS:
-3.16
Netto-Cashflow:
$-176.27M
1W Leistung:
-1.23%
1M Leistung:
+7.24%
6M Leistung:
-20.48%
1J Leistung:
+2.88%
1-Tages-Spanne:
Value
$9.12
$9.69
1-Wochen-Bereich:
Value
$9.12
$9.93
52-Wochen-Spanne:
Value
$6.44
$17.00

Replimune Group Inc Stock (REPL) Company Profile

Name
Firmenname
Replimune Group Inc
Name
Telefon
(781) 222-9600
Name
Adresse
500 UNICORN PARK, WOBURN, MA
Name
Mitarbeiter
479
Name
Twitter
@Replimune
Name
Nächster Verdiensttermin
2025-02-11
Name
Neueste SEC-Einreichungen
Name
REPL's Discussions on Twitter

Vergleichen Sie REPL mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
REPL
Replimune Group Inc
9.69 780.89M 0 -209.96M -176.27M -3.16
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
456.75 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
547.09 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
324.57 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
555.67 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
246.00 28.51B 3.81B -644.79M -669.77M -6.24

Replimune Group Inc Stock (REPL) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2024-08-28 Eingeleitet ROTH MKM Buy
2023-04-17 Fortgesetzt Piper Sandler Overweight
2021-11-19 Eingeleitet Piper Sandler Overweight
2021-10-15 Fortgesetzt BTIG Research Buy
2020-11-17 Eingeleitet BTIG Research Buy
2020-11-02 Eingeleitet Jefferies Buy
2020-10-15 Hochstufung H.C. Wainwright Neutral → Buy
2020-07-01 Herabstufung H.C. Wainwright Buy → Neutral
2020-05-05 Eingeleitet Barclays Overweight
2019-09-04 Eingeleitet ROTH Capital Buy
2019-07-23 Eingeleitet Chardan Capital Markets Buy
2019-07-12 Hochstufung JP Morgan Neutral → Overweight
2019-07-08 Eingeleitet H.C. Wainwright Buy
2019-04-25 Eingeleitet Wedbush Outperform
2019-01-23 Herabstufung JP Morgan Overweight → Neutral
2018-08-14 Eingeleitet JP Morgan Overweight
2018-08-14 Eingeleitet Leerink Partners Outperform
Alle ansehen

Replimune Group Inc Aktie (REPL) Neueste Nachrichten

pulisher
Jun 17, 2025

GAMMA Investing LLC Boosts Stock Position in Replimune Group, Inc. (NASDAQ:REPL) - Defense World

Jun 17, 2025
pulisher
Jun 14, 2025

Replimune Group, Inc. (NASDAQ:REPL) Shares Sold by Bank of America Corp DE - Defense World

Jun 14, 2025
pulisher
Jun 12, 2025

California State Teachers Retirement System Boosts Holdings in Replimune Group, Inc. (NASDAQ:REPL) - Defense World

Jun 12, 2025
pulisher
Jun 11, 2025

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 15,402 Shares of Replimune Group, Inc. (NASDAQ:REPL) - Defense World

Jun 11, 2025
pulisher
Jun 08, 2025

Squarepoint Ops LLC Cuts Stock Position in Replimune Group, Inc. (NASDAQ:REPL) - Defense World

Jun 08, 2025
pulisher
Jun 07, 2025

Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Jun 07, 2025
pulisher
Jun 06, 2025

Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | REPL Stock News - GuruFocus

Jun 06, 2025
pulisher
Jun 06, 2025

Replimune Group, Inc. Grants Inducement Equity Awards to New Employees Under 2025 Plan - Nasdaq

Jun 06, 2025
pulisher
Jun 06, 2025

Replimune Group, Inc. (REPL) Stock Analysis: A Biotech Gem with 124% Potential Upside - DirectorsTalk Interviews

Jun 06, 2025
pulisher
Jun 03, 2025

JPMorgan reiterates overweight rating on Replimune stock after ASCO By Investing.com - Investing.com Canada

Jun 03, 2025
pulisher
Jun 03, 2025

Replimune Group (NASDAQ:REPL) Price Target Raised to $22.00 at Piper Sandler - Defense World

Jun 03, 2025
pulisher
Jun 02, 2025

Piper Sandler raises Replimune stock price target after updates By Investing.com - Investing.com South Africa

Jun 02, 2025
pulisher
Jun 02, 2025

Piper Sandler raises Replimune stock price target after updates - Investing.com Australia

Jun 02, 2025
pulisher
Jun 02, 2025

Does Replimune Group Inc (NASDAQ: REPL) Still Need To Convince Analysts? - Stocksregister

Jun 02, 2025
pulisher
Jun 02, 2025

Replimune Group (REPL) Price Target Raised by Piper Sandler Anal - GuruFocus

Jun 02, 2025
pulisher
Jun 02, 2025

Replimune Group (REPL) Price Target Raised by Piper Sandler Analyst | REPL Stock News - GuruFocus

Jun 02, 2025
pulisher
Jun 02, 2025

Replimune (REPL) Price Target Raised by Piper Sandler Amid Positive Developments | REPL Stock News - GuruFocus

Jun 02, 2025
pulisher
Jun 02, 2025

BNP Paribas Financial Markets Trims Stake in Replimune Group, Inc. (NASDAQ:REPL) - Defense World

Jun 02, 2025
pulisher
Jun 01, 2025

Replimune (REPL) Highlights Promising RP1 Data at ASCO 2025 | REPL Stock News - GuruFocus

Jun 01, 2025
pulisher
Jun 01, 2025

Replimune Presents New Analyses from the IGNYTE Study of RP1 plu - GuruFocus

Jun 01, 2025
pulisher
Jun 01, 2025

Replimune Presents New Analyses from the IGNYTE Study of RP1 plus Nivolumab in Anti-PD1 Failed Melanoma at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting | REPL Stock News - GuruFocus

Jun 01, 2025
pulisher
Jun 01, 2025

Replimune Reports Promising Clinical Data for RP1 Plus Nivolumab at ASCO 2025, Highlighting Robust Responses and Safety Profile - Nasdaq

Jun 01, 2025
pulisher
Jun 01, 2025

Replimune Presents New Analyses From The IGNYTE Study Of RP1 Plus Nivolumab In Anti-PD1 Failed Melanoma At The 2025 American Society Of Clinical Oncology (ASCO) Annual Meeting - marketscreener.com

Jun 01, 2025
pulisher
Jun 01, 2025

Replimune Presents New Analyses from the IGNYTE Study of RP1 plus Nivolumab in Anti-PD1 Failed ... - Enidnews.com

Jun 01, 2025
pulisher
Jun 01, 2025

Replimune's RP1 Achieves 33% Response Rate in Anti-PD1 Failed Melanoma Trial | REPL Stock News - Stock Titan

Jun 01, 2025
pulisher
Jun 01, 2025

ProShare Advisors LLC Grows Stock Position in Replimune Group, Inc. (NASDAQ:REPL) - Defense World

Jun 01, 2025
pulisher
Jun 01, 2025

Replimune Group (NASDAQ:REPL) Trading Down 5.9% – Time to Sell? - Defense World

Jun 01, 2025
pulisher
May 31, 2025

Replimune Group, Inc. (NASDAQ:REPL) Receives Consensus Rating of “Buy” from Analysts - Defense World

May 31, 2025
pulisher
May 29, 2025

Replimune to Present at the 2025 Jefferies Global Healthcare Conference - The Manila Times

May 29, 2025
pulisher
May 29, 2025

Replimune Group, Inc. (NASDAQ:REPL) Shares Acquired by Nuveen Asset Management LLC - Defense World

May 29, 2025
pulisher
May 28, 2025

Why Okta Stock Plunged on Wednesday - The Globe and Mail

May 28, 2025
pulisher
May 26, 2025

HC Wainwright Estimates Replimune Group Q3 Earnings - Defense World

May 26, 2025
pulisher
May 26, 2025

Leerink Partnrs Estimates Replimune Group Q1 Earnings - Defense World

May 26, 2025
pulisher
May 24, 2025

Replimune’s SWOT analysis: biotech firm’s stock poised for growth amid FDA review - Investing.com India

May 24, 2025
pulisher
May 23, 2025

Replimune director sells $260,168 in common stock By Investing.com - Investing.com South Africa

May 23, 2025
pulisher
May 23, 2025

Replimune Group, Inc. (NASDAQ:REPL) Q4 2025 Earnings Call Transcript - Insider Monkey

May 23, 2025
pulisher
May 23, 2025

Replimune (REPL) Plans Major Stock Sale with 25.1M Shares Offeri - GuruFocus

May 23, 2025
pulisher
May 23, 2025

Replimune Group Inc Files For Offer & Resale Of 25.1 Million Shares Of Common Stock Offered By Selling StockholdersSEC Filing - marketscreener.com

May 23, 2025
pulisher
May 23, 2025

Replimune Group Inc Files For Mixed Shelf Of Up To $250 MillionSEC Filing - marketscreener.com

May 23, 2025
pulisher
May 23, 2025

Replimune (REPL) Announces $250 Million Securities Shelf Filing | REPL Stock News - GuruFocus

May 23, 2025
pulisher
May 23, 2025

Replimune Group, Inc. (REPL) Stock Analysis: An Insight into a Biotech Gem with 141% Upside Potential - DirectorsTalk Interviews

May 23, 2025
pulisher
May 23, 2025

Replimune Group Inc (REPL) Q4 2025 Earnings Call Highlights: Strategic Advances Amid Financial ... - Yahoo Finance

May 23, 2025
pulisher
May 23, 2025

Stock Traders Buy High Volume of Call Options on Replimune Group (NASDAQ:REPL) - Defense World

May 23, 2025
pulisher
May 23, 2025

Replimune Group Inc (REPL) Q4 2025 Earnings Call Highlights: Strategic Advances Amid Financial Challenges - GuruFocus

May 23, 2025
pulisher
May 23, 2025

Replimune director sells $260,168 in common stock - Investing.com Australia

May 23, 2025
pulisher
May 23, 2025

Replimune Group Advances Oncolytic Immunotherapy Pipeline - TipRanks

May 23, 2025
pulisher
May 22, 2025

Replimune’s chief commercial officer sells $30,179 in stock By Investing.com - Investing.com South Africa

May 22, 2025
pulisher
May 22, 2025

Replimune Group, Inc. SEC 10-K Report - TradingView

May 22, 2025
pulisher
May 22, 2025

REPLIMUNE GROUP Earnings Results: $REPL Reports Quarterly Earnings - Nasdaq

May 22, 2025

Finanzdaten der Replimune Group Inc-Aktie (REPL)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Replimune Group Inc-Aktie (REPL) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
Xynos Konstantinos
Chief Medical Officer
May 20 '25
Sale
8.06
7,952
64,093
146,933
Schwendenman Andrew
Chief Accounting Officer
May 20 '25
Sale
8.05
3,287
26,460
68,284
Patel Sushil
Chief Executive Officer
May 20 '25
Sale
8.06
25,105
202,346
343,576
Hill Emily Luisa
Chief Financial Officer
May 20 '25
Sale
8.05
2,535
20,407
143,522
Sarchi Christopher
Chief Commercial Officer
May 20 '25
Sale
8.05
3,749
30,179
128,296
Patel Sushil
Chief Executive Officer
Dec 16 '24
Sale
12.42
10,000
124,200
202,014
$21.00
price up icon 1.52%
$36.00
price down icon 0.06%
$21.32
price down icon 0.15%
$99.07
price down icon 1.72%
$108.80
price up icon 2.21%
biotechnology ONC
$244.86
price up icon 1.07%
Kapitalisierung:     |  Volumen (24h):